Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Center of Excellence for Medical Genomics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand.
Neuromuscul Disord. 2020 Oct;30(10):851-858. doi: 10.1016/j.nmd.2020.08.362. Epub 2020 Aug 29.
Congenital myasthenic syndromes (CMS) comprise a heterogeneous group of genetic disorders of the neuromuscular junction. Next generation sequencing has been increasingly used for molecular diagnosis in CMS patients. This study aimed to identify the disease-causing variants in Thai patients. We recruited patients with a diagnosis of CMS based on clinical and electrophysiologic findings, and whole exome sequencing was performed. Thirteen patients aged from 2 to 54 years (median: 8 years) from 12 families were enrolled. Variants were identified in 9 of 13 patients (69%). Five novel variants and two previously reported variant were found in the COLQ, RAPSN and CHRND gene. The previously reported c.393+1G>A splice site variant in the COLQ gene was found in a majority of patients. Five patients harbor the homozygous splice site c.393+1G>A variant, and two patients carry compound heterozygous c.393+1G>A, c.718-1G>T, and c.393+1G>A, c.865G>T (p.Gly289Ter) variants. The novel variants were also found in RAPSN (p.Cys251del, p.Arg282Cys) and CHRND (p.Met481del). Molecular diagnosis in CMS patients can guide treatment decisions and may be life changing, especially in patients with COLQ mutations.
先天性肌无力综合征(CMS)是一组神经肌肉接头遗传疾病的异质性疾病。下一代测序已越来越多地用于 CMS 患者的分子诊断。本研究旨在鉴定泰国患者的致病变异。我们根据临床和电生理发现招募了 CMS 诊断患者,并进行了全外显子组测序。从 12 个家庭中招募了 13 名年龄在 2 至 54 岁(中位数:8 岁)的患者。在 13 名患者中的 9 名(69%)发现了变异。在 COLQ、RAPSN 和 CHRND 基因中发现了 5 个新的变异和 2 个先前报道的变异。COLQ 基因中先前报道的 c.393+1G>A 剪接位点变异在大多数患者中发现。5 名患者携带纯合剪接位点 c.393+1G>A 变异,2 名患者携带复合杂合 c.393+1G>A、c.718-1G>T 和 c.393+1G>A、c.865G>T(p.Gly289Ter)变异。新的变异也在 RAPSN(p.Cys251del、p.Arg282Cys)和 CHRND(p.Met481del)中发现。CMS 患者的分子诊断可以指导治疗决策,并且可能改变生活,特别是在 COLQ 突变患者中。